BUZZ-U.S. STOCKS ON THE MOVE-Geron, Vivint, Greif, Kythera, Roundy's
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stocks were little changed on Thursday, in the wake of two days of declines on the S&P 500, as gains were curbed by a higher-than-expected initial jobless claims report ahead of a report on factory orders. The Dow Jones industrial average was up 0.27 percent at 18,146.36, the S&P 500 was up 0.21 percent at 2,102.87 and the Nasdaq Composite was up 0.43 percent at 4,988.483.
** SECOND SIGHT MEDICAL PRODUCTS INC, $17.3, +16.03 pct
The artificial retina maker completed its first commercial implant of Argus II Retinal Prosthesis at two new centers in Italy. Argus II is the first visual prosthetic that provides functional vision to patients suffering from inherited vision loss.
** PHARMACYCLICS INC, $254.551, +10.44 pct
** ABBVIE INC, $57.11, -5.24 pct
AbbVie will buy Pharmacyclics for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. The deal, the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline, confounds expectations that Pharmacyclics would sell out to Johnson & Johnson.